Form 8-K REVIVA PHARMACEUTICALS For: May 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Reviva Pharmaceuticals (RVPH) Enters $50M ATM Offering
May 30, 2025 4:13 PM EDTOn May 30, 2025, Reviva Pharmaceuticals (NASDAQ: RVPH) entered into an At Market Issuance Sales Agreement (the Agreement) with B. Riley Securities, Inc. and Alliance Global Partners, serving as agents (the Agents), with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the Common Stock), having an aggregate offering price of up to $50 million (the Shares) through the Agents (the Offering). Any Shares offered and sold in the Offering will be issued pursuant to... More
